Summary
p53 gene mutation is the most common genetic alteration in neoplastic diseases, including breast cancer, for which p53 alteration may indicate poor prognosis. Recent clinical evidence suggests that prostate-specific antigen (PSA) expression may identify breast cancer patients with favourable outcome. Assessment of p53 and PSA in combination, potentially offering improved prediction, has not yet been performed. Extracts from 952 primary breast carcinomas were assayed for PSA and p53 by quantitative enzyme-linked immunosorbent assays (ELISAs) developed by the authors. Concentrations of each marker were classified as negative or positive on the basis of median and 30th percentile cut-off points for p53 and PSA respectively. Patients followed for a median of 6 years having different combinations of negative or positive status for PSA and p53 were compared with respect to the relative risks (RRs) for relapse and death by Cox proportional hazards regression analysis, in which an interaction term was also evaluated, and with respect to disease-free survival (DFS) and overall survival (OS) probabilities by Kaplan–Meier plots and log-rank tests. Multivariate models were adjusted for oestrogen and progesterone receptor status, nodal status, patient age, tumour size, DNA ploidy, S phase fraction and receipt of chemotherapy. Interactions were not found between the status of PSA and p53 in the Cox models, in which PSA-negativity (RR = 1.47, P = 0.020 for DFS, and RR = 1.49, P = 0.023 for OS) and p53-positivity (RR = 1.46, P = 0.017 for DFS, and RR = 1.41, P = 0.033 for OS) were individually associated with prognosis. Evaluation of a combined three-level variable revealed that PSA(–)/p53(+) patients had significantly higher risks for relapse (RR = 2.13, P < 0.001) and death (RR = 2.08, P = 0.001) than PSA(+)/p53(–) patients, and that patients positive or negative for both markers had intermediate risks for the outcome events in the same multivariate analysis (RR = 1.45 for both DFS and OS). The results of our study demonstrate that the assessment of combined PSA and p53 expression status by ELISAs, easily applicable to breast tumour extracts prepared for steroid hormone receptor analyses, may stratify breast cancer patients into groups differing by relapse and death risks of greater magnitude than offered by the assessment of either p53 or PSA alone.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Allred, DC, Clark, GM, Elledge, R, Fuqua, SAW, Brown, RW, Chamness, GC, Osborne, CK & McGuire, WL (1993). Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200–206.
Borg, A, Lennerstrand, J, Stenmark-Askmalm, M, Ferno, M, Brisfors, A, Ohrvik, A, Stal, O, Killander, D, Lane, D & Brundell, J (1995). Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer 71: 1013–1017.
Buckbinder, L, Talbott, R, Velasco-Miguel, S, Takenaka, I, Faha, B, Seizinger, BR & Kley, N (1995). Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646–649.
Chang, F, Syrjanen, Tervahauta, A & Syrjanen, K (1993). Tumorigenesis associated with the p53 tumour suppressor gene. Br J Cancer 68: 653–661.
Clark, GM & McGuire, WL (1983). Progesterone receptors and human breast cancer. Breast Cancer Res Treat 3: 157–163.
Clark, GM, Dressler, LG, Owens, MA, Pounds, G, Oldaker, T & McGuire, WL (1989). Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320: 627–633.
Clements, J & Mukhtar, A (1994). Glandular kallikreins and prostate specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab 78: 1536–1539.
Cohen, P, Graves, HCB, Peehl, DM, Kamarel, M, Giudice, LC & Rosenfeld, RG (1992). Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 75: 1046–1053.
Cohen, P, Peehl, DM, Graves, HCB & Rosenfeld, RG (1994). Biological effects of prostate specific antigen as an insulin-like growth factor-binding-3 protease. J Endocrinol 142: 407–415.
Cox, DR (1972). Regression models and life tables. J R Stat Soc B 34: 187–202.
de Witte, HH, Koekens, JA, Lennerstrand, J, Smid, M, Look, MP, Klijn, JGM, Benraad, TJ & Berns, EMJJ (1996). Prognostic significance of TP53 accumulation in human primary breast cancer: comparison between a rapid quantitative immunoassay and SSCP analysis. Int J Cancer 69: 125–130.
Diamandis, EP & Levesque, M (1995). Assessment of p53 protein overexpression by non-immunohistochemical methods. J Pathol 175: 93–94.
Diamandis, EP, Yu, H & Sutherland, DJA (1994). Detection of prostate specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 32: 291–300.
Diamandis, EP, Yu, H & Lopez-Otin, C (1996). Prostate specific antigen – a new constituent of breast cyst fluid. Breast Cancer Res Treat 38: 259–264.
Dressler, LG, Seamer, LC, Owens, MA, Clark, GM & McGuire, WL (1988). DNA flow cytometry and prognostic factors in 1131 frozen breast cancer specimens. Cancer 61: 420–427.
Ferguson, RA, Yu, H, Kalyvas, M, Zammit, S & Diamandis, EP (1996). Ultrasensitive detection of prostate specific antigen by a new time resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin Chem 42: 675–684.
Gasparini, G, Pozza, F & Harris, AL (1993). Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85: 1206–1219.
Greenblatt, MS, Bennett, WP, Hollstein, M & Harris, CC (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855–4878.
Hartwell, LH & Kastan, MB (1994). Cell cycle control and cancer. Science 266: 1821–1828.
Kaplan, EL & Meier, P (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481.
Karp, JE & Broder, S (1995). Molecular foundations of cancer: new targets for intervention. Nature Med 1: 309–320.
Lane, DP (1994). The regulation of p53 function. Int J Cancer 57: 623–627.
Levesque, MA, Clark, GM, Yu, H & Diamandis, EP (1995a). Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators. Br J Cancer 72: 720–727.
Levesque, MA, D’Costa, M, Angelopoulou, K & Diamandis, EP (1995b). Time-resolved immunofluorometric assay of p53. Clin Chem 41: 1720–1729.
Levesque, MA, Yu, H, Clark, GM & Diamandis, EP (1998). ELISA-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort. J Clin Oncol 16: 2641–2650.
Levine, AJ, Perry, ME, Chang, A, Silver, A, Dittmer, D, Wu, M & Welsh, D (1994). The role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 69: 409–416.
Lianidou, ES, Levesque, MA, Katsaros, D, Angelopoulou, K, Yu, H, Genta, F, Arisio, R, Massobrio, M, Bharaj, B & Diamandis, EP (1999). Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma. Anticancer Res 19: 749–756.
Mantel, N (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163–170.
McGuire, WL & Clark, GM (1992). Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326: 1756–1761.
Oesterling, JE (1989). Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907–923.
Partin, AW & Oesterling, JE (1994). The clinical usefulness of prostate specific antigen: update 1994. J Urol 152: 1358–1368.
Pollen, JJ & Dreilinger, A (1984). Immunohistochemical identification of prostatic acid phosphatase and prostate specific antigen in female periurethral gland. Urology 23: 303–304.
Pummer, K, Wirnsberger, G, Purstner, P, Stettner, H & Wandschneider, G (1992). False positive prostate specific antigen values in the sera of women with renal cell carcinoma. J Urol 148: 21–23.
Sjögren, S, Inganas, M, Norberg, T, Lindgren, A, Nordgren, H, Holmberg, L & Bergh, J (1996). The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88: 173–182.
Soussi, T, Legros, Y, Lubin, R & Ory, K, Schlichtholz (1994). Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 57: 1–9.
Thor, AD, Moore, DH, Edgerton, SM, Kawasaki, ES, Reihsaus, E, Lynch, HT, Marcus, JN, Schwartz, L, Chen, LC, Mayall, BH & Smith, HS (1992). Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. J Natl Cancer Inst 84: 845–855.
Yu, H & Diamandis, EP (1995a). Prostate specific antigen immunoreactivity in amniotic fluid. Clin Chem 41: 204–210.
Yu, H & Diamandis, EP (1995b). Prostate specific antigen in milk of lactating women. Clin Chem 41: 54–60.
Yu, H, Diamandis, EP & Sutherland, DJA (1994a). Immunoreactive prostate specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patients age. Clin Biochem 27: 75–79.
Yu, H, Diamandis, EP, Zarghami, N & Grass, L (1994b). Induction of prostate specific antigen production by steroids and tamoxifen in the breast cancer cell lines. Breast Cancer Res Treat 32: 301–310.
Yu, H, Diamandis, EP, Levesque, MA, Asa, SL, Monne, M & Croce, CM (1995a). Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. Cancer Res 55: 1603–1606.
Yu, H, Giai, M, Diamandis, EP, Katsaros, D, Sutherland, DJA, Levesque, MA, Roagna, R, Ponzone, R & Sismondi, P (1995b). Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 55: 2104–2110.
Yu, H, Diamandis, EP, Levesque, M, Giai, M, Roagna, R, Ponzone, R, Sismondi, P, Monne, M & Croce, M (1996). Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 40: 171–178.
Yu, H, Levesque, MA, Clark, GM & Diamandis, EP (1998). Prognostic value of prostate specific antigen for women with breast cancer – a large cohort study. Clin Cancer Res 4: 1489–1497.
Zarghami, N, Grass, L & Diamandis, EP (1997). Steroid hormone regulation of prostate specific antigen gene expression in breast cancer. Br J Cancer 75: 579–588.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Yu, H., Levesque, M., Clark, G. et al. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. Br J Cancer 81, 490–495 (1999). https://doi.org/10.1038/sj.bjc.6690720
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690720
Keywords
This article is cited by
-
A glassy carbon electrode modified with graphene nanoplatelets, gold nanoparticles and chitosan, and coated with a molecularly imprinted polymer for highly sensitive determination of prostate specific antigen
Microchimica Acta (2017)
-
Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer
Investigational New Drugs (2007)